The American journal of managed care

How well heart health study rules for GLP-1 diabetes drugs apply to people with type 2 diabetes in the US

GLP-1 Therapies Weekly Brief ↗PubMed ↗

Updated

Abstract

More than 60% of adults with type 2 diabetes (T2D) in the United States may qualify for at least one glucagon-like peptide-1 receptor agonist cardiovascular outcomes trial.

  • The proportion of adults with T2D eligible for specific cardiovascular outcomes trials varied from 6.4% to 47.2%.
  • EXSCEL had the most generalizable inclusion criteria among the trials evaluated.
  • ELIXA had the least generalizable eligibility criteria.
  • The evaluation was based on data from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2012.

Simplified

Related papers

Sep '18
Do Drugs That Activate Glucagon-Like Peptide-1 Receptors Lower Heart Risks in Type 2 Diabetes as a Group?
top 20% journal
cited by 25 papers
journal article
Sep '20
Heart safety of once-weekly GLP-1 treatments in people with type 2 diabetes
top 50% journal
cited by 8 papers
journal article
Jan '20
Diabetes heart trial participant rules may not reflect typical patients: The example of GLP-1 receptor drugs
cited by 24 papers
research support, non-u.s. gov't
Aug '19
Heart, death, and kidney outcomes linked to GLP-1 receptor drugs in people with type 2 diabetes
top 1% journal
cited by 1,386 papers
systematic review
Dec '17
Heart and blood vessel outcomes linked to glucagon-like peptide-1 receptor drugs in people with type 2 diabetes: a combined analysis
top 1% journal
cited by 541 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
6 days ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
1 week ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
3 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
4 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
5 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
6 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
7 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
8 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief